Boston Scientific exec to head JenaValve
This article was originally published in Clinica
German transcatheter aortic valve developer JenaValve has appointed Boston Scientific alumna Victoria Carr-Brendel CEO. Dr Carr-Brendel replaces Jans Keltjens, who took the helm on an interim basis after David Drachman left the post in January this year; Mr Drachman resigned after only six months as CEO due to “non-business-related personal reasons”. Mr Keltjens will remain chairman of the JenaValve board and support Dr Carr-Brendel during the transition period.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.